Table 1.
Q1 (affluent), N (%) | Q2, N (%) | Q3, N (%) | Q4, N (%) | Q5 (deprived), N (%) | Total, N (%) | Test |
||
χ2 (df) | p Value | |||||||
All patients | 2111 (100) | 2550 (100) | 3035 (100) | 3817 (100) | 4069 (100) | 15 582 (100) | ||
Sex | ||||||||
Male | 1208 (57.2) | 1458 (57.2) | 1708 (56.3) | 2165 (56.7) | 2358 (58) | 8897 (57.1) | ||
Female | 903 (42.8) | 1092 (42.8) | 1327 (43.7) | 1652 (43.3) | 1711 (42) | 6685 (42.9) | 0.31 (1) | 0.57 |
Age at diagnosis | ||||||||
0–59 | 310 (14.7) | 329 (12.9) | 430 (14.2) | 637 (16.7) | 752 (18.5) | 2458 (15.8) | ||
60–69 | 497 (23.5) | 617 (24.2) | 743 (24.5) | 990 (25.9) | 1086 (26.7) | 3933 (25.2) | ||
70–79 | 751 (35.6) | 869 (34.1) | 1009 (33.2) | 1241 (32.5) | 1302 (32) | 5172 (33.2) | ||
80+ | 553 (26.2) | 735 (28.8) | 853 (28.1) | 949 (24.9) | 929 (22.8) | 4019 (25.8) | 66.7 (1) | <0.01 |
Charlson Score | ||||||||
0 | 897 (49.8) | 1065 (47.5) | 1217 (45.5) | 1496 (43.8) | 1494 (41.1) | 6169 (44.8) | ||
1 | 476 (26.4) | 621 (27.7) | 754 (28.2) | 942 (27.6) | 1064 (29.3) | 3857 (28) | ||
2+ | 428 (23.8) | 555 (24.8) | 704 (26.3) | 981 (28.7) | 1075 (29.6) | 3743 (27.2) | 53.8 (1) | <0.01 |
Missing | 310 (–) | 309 (–) | 360 (–) | 398 (–) | 436 (–) | 1813 (–) | ||
Histologic type | ||||||||
NSCLC | 961 (45.5) | 1058 (41.5) | 1236 (40.7) | 1515 (39.7) | 1623 (39.9) | 6393 (41) | ||
Other specified | 39 (1.8) | 47 (1.8) | 54 (1.8) | 61 (1.6) | 60 (1.5) | 261 (1.7) | ||
SCLC | 197 (9.3) | 259 (10.2) | 311 (10.2) | 440 (11.5) | 485 (11.9) | 1692 (10.9) | ||
Unspecified | 914 (43.3) | 1186 (46.5) | 1434 (47.2) | 1801 (47.2) | 1901 (46.7) | 7236 (46.4) | 27.4 (12) | <0.01 |
Stage at diagnosis | ||||||||
IA–IIB | 236 (15.4) | 341 (18.6) | 369 (16.9) | 492 (17.9) | 480 (15.8) | 1918 (16.9) | ||
IIIA–IV | 1296 (84.6) | 1496 (81.4) | 1812 (83.1) | 2250 (82.1) | 2556 (84.2) | 9410 (83.1) | 0.18 (1) | 0.67 |
Unknown | 579 (–) | 713 (–) | 854 (–) | 1075 (–) | 1033 (–) | 4254 (–) |